Omnicell, Inc. (NASDAQ:OMCL) Analyst Ratings as of Apr 16, 2018

April 16, 2018 - By Nell Hawkins

Omnicell, Inc. (NASDAQ:OMCL) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.12. That’s change of 0.10, from 2017Q3’s 1.02. 14 investors sold all, 72 reduced holdings as Omnicell, Inc. ratio improved. 69 increased positions while 27 funds acquired positions. Funds hold 37.38 million shares thus 0.77% more from 2017Q3’s 37.10 million shares.
West Coast Financial Lc has invested 1.55% of its capital in Omnicell, Inc. (NASDAQ:OMCL). 97,386 are held by Comerica National Bank. Moreover, Brinker Capital has 0.01% invested in Omnicell, Inc. (NASDAQ:OMCL) for 7,768 shs. Moreover, King Luther Capital Mgmt has 0.03% invested in Omnicell, Inc. (NASDAQ:OMCL) for 71,355 shs. First Mercantile Tru reported 0.08% in Omnicell, Inc. (NASDAQ:OMCL). Advisory Research owns 34,485 shs. Regions Corp accumulated 8,484 shs. 117,875 are held by Pier Capital Limited Liability. Torray Limited Liability Corporation reported 20,992 shs. Daruma Capital Mngmt Limited Liability Corp holds 970,386 shs. The Pennsylvania-based Sei Company has invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Ubs Asset Americas has 0.01% invested in Omnicell, Inc. (NASDAQ:OMCL) for 129,761 shs. Price T Rowe Associate Md reported 655,716 shs. Polar Cap Llp owns 540,938 shs for 0.27% of their capital. California Pub Employees Retirement Systems reported 87,628 shs.

Omnicell, Inc. had 4 insider sales and 0 insider buys since December 15, 2017. This’s net activity of $520,345. 8,186 shs were sold by LIPPS RANDALL A, worth $361,938 on Tuesday, March 6. On Thursday, March 15 PETERSMEYER GARY S sold $25,544 worth of Omnicell, Inc. (NASDAQ:OMCL) or 575 shs.

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

Total analysts of 5 have positions in Omnicell (NASDAQ:OMCL) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since October 19, 2017 according to StockzIntelligence Inc Omnicell has 11 analyst reports. On Tuesday, December 5 the rating was maintained by Cantor Fitzgerald with “Buy”. The company rating was maintained by Cantor Fitzgerald on Thursday, October 26. On Friday, October 27 Piper Jaffray maintained Omnicell, Inc. (NASDAQ:OMCL) rating. Piper Jaffray has “Hold” rating and $38.0 target. On Friday, February 2 the stock of Omnicell, Inc. (NASDAQ:OMCL) earned “Hold” rating by Craig Hallum. In Tuesday, December 5 report Oppenheimer maintained it with “Buy” rating and $55.0 target. On Friday, February 2 the firm has “Neutral” rating given by PiperJaffray. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, February 1. On Monday, January 29 the firm earned “Buy” rating by Oppenheimer. On Friday, October 27 Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) with “Buy” rating. On Monday, October 30 the rating was maintained by Craig Hallum with “Buy”. Listed here are Omnicell, Inc. (NASDAQ:OMCL) PTs and latest ratings.

02/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $44 Maintain
02/02/2018 Broker: Craig Hallum Rating: Hold Downgrade
01/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0 Maintain
29/01/2018 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
05/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $60.0 Maintain
05/12/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
30/10/2017 Broker: Craig Hallum Rating: Buy New Target: $62.0 Maintain
27/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $38.0 Maintain
27/10/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
26/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $58.0 Maintain

OMCL reached $44.9 on during the last trading session after $0.15 change.Omnicell, Inc. has volume of 112,363 shares. Since April 16, 2017 OMCL has risen 5.20% and is uptrending. OMCL underperformed by 6.35% the S&P500.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.The firm is worth $1.75 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence.The P/E ratio is 84.72. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.